Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 14 results found. Search for [ Sun Pharma Q2 result ]

Results 1 to 14 of 14
PB Jayakumar
New Delhi, November 8, 2019
Sun Pharma Q2 results: The drugmaker, which earns 37 per cent of its business from the US market, earned Rs 2,389.77 crore from the sale of formulations in the US in Q2FY20 against Rs 2397 crore in the corresponding quarter of the previous year


BusinessToday.In
New Delhi, November 7, 2019
BPCL Q2 results: Revenue from operations decreased 9.48 per cent to Rs 75,057 crore in July-September of this fiscal as against Rs 82,924 crore in Q2FY19. The figure stood at Rs 85,860 crore in June quarter this year


BusinessToday.In
New Delhi, November 7, 2019
Sun Pharma Q2 results: India sales, which accounted for 31.6 per cent of total consolidated sales, rose 35 per cent year-on-year (YoY) to Rs 2,515 crore in September quarter of this fiscal


BusinessToday.In
November 7, 2019
Sun Pharma Q2 result today: The drug major's share price was trading higher ahead of the firm's Q2 earnings


E Kumar Sharma
New Delhi, November 2, 2019
Dr Reddy's CFO Saumen Chakraborty attributed much of the challenges in the US market to price erosion and lower volumes


PTI
October 10, 2019



PTI
December 3, 2018



E Kumar Sharma
October 26, 2018
The pharma major had posted a robust performance in the June quarter of FY19, largely aided by the launch in the US of gSuboxone, the generic version of the drug to deal opioid addiction.


PTI
October 15, 2018



BusinessToday.in
New Delhi, February 14, 2018
Sun Pharma in a BSE filing said that its net profit was adversely impacted by one-time deferred tax adjustment of Rs 513 crore related to changes in US tax rates.


E Kumar Sharma
New Delhi, August 17, 2017
On August 3rd, the largest generic company operating in the US, Teva Pharmaceutical Industries (Teva in quickspeak) put out results that arguably jolted the world of global generic medicines.


Suveen Sinha and Ajay Modi
November 20, 2014
The families of Fortis-Religare, Jubilant, Emami and DCM Shriram present a heartwarming contrast to the all around upheaval in family-run businesses.


Dipak Mondal
Delhi, November 3, 2014
The figures confirm that companies in the capital goods, metals and infrastructure sectors have been hit the hardest, along with those in drugs and pharmaceuticals.


BT Online Bureau
Mumbai, October 14, 2013
After gaining 633.49 points in the previous four sessions, the 30-share index of the Bombay Stock Exchange rose 78.95 points, or 0.38 per cent, to 20,607.54.


PAGES 1 OF 1